Eton Pharmaceuticals (ETON) Income from Continuing Operations (2018 - 2025)
Eton Pharmaceuticals (ETON) reported Income from Continuing Operations of 1696000.0 for Q4 2025, up 383.61% on a YoY basis from 350694.33 in Q4 2024, and up 188.01% sequentially from 1927000.0 in Q3 2025.
Eton Pharmaceuticals (ETON) Income from Continuing Operations (2018 - 2025) Analysis & Trends
Eton Pharmaceuticals (ETON) has 8 years of Income from Continuing Operations data on file, last reported at 1696000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations rose 383.61% year-over-year to 1696000.0; the trailing twelve-month figure through Dec 2025 stood at 4388000.0 (down 14.78% YoY), and the FY2025 full-year result was 4388000.0, down 14.78% from the prior year.
- Income from Continuing Operations grew to 1696000.0 in Q4 2025, from 1927000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 5116000.0 in Q1 2021 to a low of 6094000.0 in Q3 2021.
- A 5-year average of 891850.0 and a median of 1565000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations jumped 392.62% in 2023 and sank 407.34% in 2025, its largest moves.
- Tracing ETON's Income from Continuing Operations over 5 years: stood at 1039000.0 in 2021, then jumped by 170.07% to 2806000.0 in 2022, then sank by 166.43% to 1864000.0 in 2023, then soared by 67.92% to 598000.0 in 2024, then surged by 383.61% to 1696000.0 in 2025.
- Business Quant data shows ETON's Income from Continuing Operations at 1696000.0 in Q4 2025, 1927000.0 in Q3 2025, and 2585000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Eton Pharmaceuticals | 1.19 Bn | 1.16 Bn | 13.10 Mn | 1.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.70 Mn |
| Sep 30, 2025 | -1.93 Mn |
| Jun 30, 2025 | -2.59 Mn |
| Mar 31, 2025 | -1.57 Mn |
| Dec 31, 2024 | -598,000.00 |
| Sep 30, 2024 | 627,000.00 |
| Jun 30, 2024 | -3.04 Mn |
| Mar 31, 2024 | -811,000.00 |
| Dec 31, 2023 | -1.86 Mn |
| Sep 30, 2023 | -579,000.00 |
| Jun 30, 2023 | 4.56 Mn |
| Mar 31, 2023 | -2.66 Mn |
| Dec 31, 2022 | 2.81 Mn |
| Sep 30, 2022 | -3.05 Mn |
| Jun 30, 2022 | -1.56 Mn |
| Mar 31, 2022 | -5.33 Mn |
| Dec 31, 2021 | 1.04 Mn |
| Sep 30, 2021 | -6.09 Mn |
| Jun 30, 2021 | -2.02 Mn |
| Mar 31, 2021 | 5.12 Mn |